Videos / Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

Dr James MacKean

Managing Prostate Cancer Treatment Update

Facilitator: Prof Andrew Sindone, Expert Panel: Dr Desmond Graham, Prof Dominic Dwyer, Dr Ted Wu

RSV, Respiratory Viral Infections and the Heart – Exert Panel

Prof Creswell Eastman AO

Thyroid Disease in Pregnancy

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

06 August 2024

expert

Dr Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD